Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 2Phase NA 1Phase EARLY_PHASE1 1Phase 1/2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 8Gastrointestinal 3Head & Neck 2Gynecologic 2

Conditions

Uterine Cervical Neoplasms 1Ovarian Neoplasms 1

Interventions

Paclitaxel 150Carboplatin 110Cisplatin 95Bevacizumab 42Topotecan 39Gemcitabine 38liposomal doxorubicin 34Radiotherapy 29Doxorubicin 27Brachytherapy 26Taxes 24pembrolizumab 20olaparib 20Drug Therapy 20Hyperthermic Intraperitoneal Chemotherapy 16Chemotherapy, Adjuvant 16human papillomavirus vaccine, L1 type 16, 18 15Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 14Docetaxel 13Neoadjuvant Therapy 12Platinum 10niraparib 9Radiation 91,2-diaminocyclohexaneplatinum II citrate 9Vaccines, Synthetic 8Surgical Procedures, Operative 8atezolizumab 7Specimen Handling 7Papillomavirus Vaccines 7Letrozole 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Platinum Compounds × Gynecologic × Clear all
NCT04906993 2025-09-09

Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Active not recruiting
443 enrolled
Gynecologic

Uterine Cervical Neoplasms

NCT02891824 2025-02-11

ATALANTE

ARCAGY/ GINECO GROUP

Phase 3 Completed
614 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡